A 62-year-old male smoker presents with central chest pain, cough, and hemoptysis. Chest X-ray shows a hilar mass with mediastinal widening. Bronchoscopic biopsy reveals small round cells with scant cytoplasm, fine chromatin, and numerous mitoses. Immunohistochemistry is positive for synaptophysin and chromogranin A. All of the following are true regarding this patient's condition EXCEPT:

Explanation

## Small Cell Lung Cancer: Clinical Features and Management ### Diagnosis and Neuroendocrine Origin **Key Point:** The clinical and histopathologic findings (small round cells, fine chromatin, high mitotic rate, positive synaptophysin and chromogranin A) confirm small cell lung cancer (SCLC). SCLC arises from **neuroendocrine (Kulchitsky) cells**, NOT from squamous metaplasia. Squamous metaplasia is associated with NSCLC (squamous cell carcinoma) [cite:Robbins 10e Ch 15]. ### Paraneoplastic Syndromes **High-Yield:** SCLC is the **most common lung cancer associated with paraneoplastic syndromes** (30–50% of cases): - **SIADH** (most common; hyponatremia) - **LEMS** (antibodies against voltage-gated calcium channels; proximal weakness, autonomic dysfunction) - Cushing syndrome (ectopic ACTH) - Myasthenia gravis - Sensory neuropathy These may precede the diagnosis of cancer [cite:Harrison 21e Ch 111]. ### Chemotherapy Response and Prognosis **Clinical Pearl:** SCLC is **exquisitely chemosensitive** — initial response rates to platinum-etoposide are 60–80%. However, **long-term remission is uncommon**, and most patients relapse within 6–12 months. Median survival: limited disease 9–11 months, extensive disease 4–6 months. ### Prophylactic Cranial Irradiation (PCI) **Key Point:** PCI is **standard of care** for patients with SCLC who achieve complete remission (CR), reducing brain metastasis incidence from ~40% to ~15% and improving overall survival by ~5% [cite:Harrison 21e Ch 111]. ### Why Option 4 Is Incorrect **Warning:** SCLC arises from **neuroendocrine cells**, not squamous metaplasia. Squamous cell carcinoma (a type of NSCLC) arises from squamous metaplasia. Additionally, SCLC has a **worse prognosis** than adenocarcinoma of the lung (5-year survival SCLC ~7% vs. adenocarcinoma ~20%). | Feature | SCLC | Squamous Cell CA | Adenocarcinoma | | --- | --- | --- | --- | | **Cell origin** | Neuroendocrine | Squamous metaplasia | Mucus-secreting cells | | **5-year survival** | ~7% | ~15% | ~20% | | **Paraneoplastic syndromes** | Common (30–50%) | Rare | Rare | | **Initial chemo response** | Excellent (60–80%) | Moderate | Moderate |